Type of malignancy | Sex | No of TNF inhibitors exposed/ csDMARD matched RA | No of cancer in TNF inhibitors exposed patients | No of cancer in csDMARD matched patients | HR | 95% CI | P value |
All malignancies excluding non-melanoma skin cancers | 16 333–16 333 | 332 | 277 | 1.03 | (0.88 to 1.21) | 0.702 | |
All solid malignancies excluding non-melanoma skin cancers | 16 333–16 333 | 290 | 232 | 1.08 | (0.91 to 1.28) | 0.405 | |
Haematological malignancies | 16 333–16 333 | 30 | 36 | 0.72 | (0.44 to 1.17) | 0.186 | |
Malignant lymphoma | 16 333–16 333 | 19 | 21 | 0.77 | (0.42 to 1.43) | 0.413 | |
Hodgkin lymphoma | 16 333–16 333 | 1 | 1 | 0.88 | (0.06 to 13.72) | 0.929 | |
Non-Hodgkin's lymphoma | 16 333–16 333 | 18 | 20 | 0.77 | (0.41 to 1.44) | 0.413 | |
Haematological malignancies (excluding lymphoma) | 16 333–16 333 | 11 | 15 | 0.65 | (0.29 to 1.41) | 0.277 | |
Invasive melanoma | 16 333–16 333 | 11 | 13 | 0.73 | (0.33 to 1.62) | 0.437 | |
Invasive cancer of the cervix | Women | 12 158–12 158 | 6 | 4 | 1.32 | (0.38 to 4.68) | 0.658 |
Breast cancer | Women | 12 158–12 158 | 66 | 50 | 1.15 | (0.80 to 1.66) | 0.450 |
Lung cancer | 16 333–16 333 | 43 | 35 | 1.04 | (0.67 to 1.63) | 0.853 | |
Colorectal cancer | 16 333–16 333 | 34 | 20 | 1.45 | (0.83 to 2.53) | 0.179 | |
Prostate cancer | Men | 4175–4175 | 22 | 26 | 0.7 | (0.40 to 1.25) | 0.235 |
Kidney cancer | 16 333–16 333 | 7 | 14 | 0.44 | (0.18 to 1.11) | 0.081 | |
Liver cancer | 16 333–16 333 | 5 | 1 | 4.29 | (0.50 to 37.14) | 0.131 | |
Pancreas cancer | 16 333–16 333 | 8 | 8 | 0.85 | (0.32 to 2.25) | 0.748 |
csDMARD, conventional synthetic DMARD; DMARD, disease-modifying antirheumatic agents; RA, rheumatoid arthritis.